Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.61 |
| ▸ | CHRNB3 | Q05901 | 8/20 | 0.61 |
| ▸ | CHRNA6 | Q15825 | 8/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938510 | 0.93 | CHRNB2 (0.65) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL7049284 | 0.90 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978271 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL18151107 | 0.73 | HPGD (0.49) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27227699 | 0.72 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL3805279 | 0.72 | CHRNB2 (0.60) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10305115 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16621833 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16621835 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20186616 | 0.71 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| EP-2149575-B1 | Diazabicyclic compounds as opioid receptor agonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-10-24 | — | — | EP | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| EP-2149575-A1 | Diazabicyclic compounds as opioid receptor agonists | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149370-A1 | Diazabicyclic compounds and microemulsions thereof | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | CHRNB2 70/4885CHRNA3 73/4885CHRNA4 75/4885 |
| US-20100029622-A1 | MICROEMULSIONS | LIPA, APOB, LIPC | CHRNB2 438/4885CHRNA3 520/4885CHRNA4 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.